BioNexus Gene Lab Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 217/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioNexus Gene Lab Corp's Score
Industry at a Glance
Industry Ranking
217 / 404
Overall Ranking
407 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioNexus Gene Lab Corp Highlights
StrengthsRisks
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.51M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.51M.
Fairly Valued
The company’s latest PE is -3.25, at a medium 3-year percentile range.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.96.
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Ticker SymbolBGLC
CompanyBioNexus Gene Lab Corp
CEOTan (Lee Su-Leng)
Websitehttps://www.bionexusgenelab.com/
FAQs
What is the current price of BioNexus Gene Lab Corp (BGLC)?
The current price of BioNexus Gene Lab Corp (BGLC) is 4.150.
What is the symbol of BioNexus Gene Lab Corp?
The ticker symbol of BioNexus Gene Lab Corp is BGLC.
What is the 52-week high of BioNexus Gene Lab Corp?
The 52-week high of BioNexus Gene Lab Corp is 15.600.
What is the 52-week low of BioNexus Gene Lab Corp?
The 52-week low of BioNexus Gene Lab Corp is 2.007.
What is the market capitalization of BioNexus Gene Lab Corp?
The market capitalization of BioNexus Gene Lab Corp is 7.46M.
What is the net income of BioNexus Gene Lab Corp?
The net income of BioNexus Gene Lab Corp is -1.60M.
Is BioNexus Gene Lab Corp (BGLC) currently rated as Buy, Hold, or Sell?
According to analysts, BioNexus Gene Lab Corp (BGLC) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of BioNexus Gene Lab Corp (BGLC)?
The Earnings Per Share (EPS TTM) of BioNexus Gene Lab Corp (BGLC) is -1.278.